Solid Biosciences Inc. (SLDB) Income Statement
SLDB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSLDB revenue and net income
SLDB profit margins
SLDB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SLDB quarterly EPS vs estimates
Solid Biosciences beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 2, 2026 (estimate $-0.37).
SLDB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $8.1M | $13.6M | $3.3M | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.6M | $2.5M | $2.6M | $2.4M | $3.0M | $3.9M | $2.8M | $1.6M | $448,000 | $56,000 |
| Gross profit | −$1.6M | −$2.5M | −$2.6M | $8.1M | $13.6M | −$3.9M | −$2.8M | −$1.6M | −$448,000 | −$56,000 |
| Research & development | $140.3M | $96.4M | $76.6M | $78.4M | $58.7M | $64.9M | $94.7M | $58.0M | $39.9M | $20.1M |
| Sales, general & admin | $38.9M | $33.3M | $27.8M | $28.9M | $27.1M | $21.6M | $24.6M | $17.7M | $15.0M | $5.5M |
| Total operating expenses | $177.6M | $127.3M | $101.7M | $114.5M | $85.9M | $82.5M | $119.3M | $75.7M | $54.9M | $25.6M |
| Operating income | −$179.2M | −$129.7M | −$104.3M | −$106.5M | −$72.3M | −$86.5M | −$119.3M | −$75.7M | −$54.9M | −$25.6M |
| Interest income | $10.1M | $9.5M | $7.0M | $2.6M | $64,000 | $115,000 | $1.6M | $619,000 | $219,000 | $369,000 |
| Interest expense | — | $340,000 | $440,000 | $20.5M | $66,000 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$174.3M | −$124.7M | −$96.0M | −$86.0M | −$72.2M | −$88.3M | −$117.2M | −$74.8M | −$53.2M | −$23.8M |
| Income taxes | — | — | — | −$20.5M | −$64,000 | $1.8M | −$1.6M | $889,000 | −$1.3M | −$2.6M |
| Net income | −$174.3M | −$124.7M | −$96.0M | −$86.0M | −$72.2M | −$88.3M | −$117.2M | −$74.8M | −$52.1M | −$21.5M |
| EBITDA | −$172.7M | −$121.9M | −$93.4M | −$96.9M | −$69.2M | −$84.4M | −$116.5M | −$74.1M | −$54.4M | −$25.5M |
| EPS (diluted) | −$2.02 | −$3.04 | −$4.85 | −$9.82 | −$10.20 | −$24.82 | −$43.95 | −$33.75 | −$13.87 | −$0.14 |
| Gross margin | — | — | — | 100.0% | 100.0% | −117.6% | — | — | — | — |
| Operating margin | — | — | — | −1,315.2% | −530.5% | −2,592.6% | — | — | — | — |
| Net margin | — | — | — | −1,062.3% | −530.0% | −2,647.4% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $3.1M | $0 | $0 | $0 | $4.7M | $0 |
| Cost of revenue | $391,000 | $395,000 | $467,000 | $376,000 | $386,000 | $407,000 | $488,000 | $405,000 | $1.2M | $327,000 | $587,000 | $588,000 |
| Gross profit | −$391,000 | −$395,000 | −$467,000 | −$376,000 | −$386,000 | −$407,000 | −$488,000 | −$405,000 | −$1.2M | −$327,000 | −$587,000 | −$588,000 |
| Research & development | $44.3M | $46.1M | $38.1M | $38.9M | $32.4M | $30.9M | $30.8M | $27.3M | $19.5M | $18.9M | $15.5M | $16.7M |
| Sales, general & admin | $13.1M | $11.2M | $11.3M | $9.2M | $9.3M | $9.1M | $9.1M | $7.9M | $8.3M | $8.0M | $6.8M | $6.4M |
| Total operating expenses | $57.0M | $56.9M | $49.4M | $48.1M | $41.3M | $39.6M | $39.9M | $35.2M | $27.8M | $26.5M | $22.3M | $23.1M |
| Operating income | −$57.4M | −$57.3M | −$49.4M | −$48.1M | −$41.7M | −$40.1M | −$39.9M | −$35.2M | −$27.8M | −$26.9M | −$22.3M | −$23.1M |
| Interest income | $3.2M | $2.1M | $2.0M | $2.9M | $3.0M | $2.3M | $1.9M | $2.3M | $2.6M | $2.7M | $1.7M | $1.9M |
| Interest expense | $0 | $0 | — | $336,000 | $60,000 | $68,000 | $75,000 | $82,000 | $88,000 | $95,000 | $2.0M | $106,000 |
| Income before taxes | −$54.8M | −$56.7M | −$49.8M | −$45.8M | −$39.5M | −$39.3M | −$42.6M | −$32.7M | −$25.1M | −$24.3M | −$20.3M | −$21.0M |
| Income taxes | — | — | — | — | — | — | $951,276 | — | −$1.2M | $283,724 | $4.6M | −$588,000 |
| Net income | −$54.8M | −$56.7M | −$49.8M | −$45.8M | −$39.5M | −$39.3M | −$42.6M | −$32.7M | −$25.1M | −$24.3M | −$20.3M | −$21.0M |
| EBITDA | −$54.4M | −$56.3M | −$49.3M | −$45.4M | −$39.0M | −$38.8M | −$42.0M | −$32.2M | −$23.7M | −$23.9M | −$20.1M | −$20.3M |
| EPS (diluted) | −$0.38 | −$0.52 | −$0.53 | −$0.48 | −$0.42 | −$0.59 | −$1.00 | −$0.79 | −$0.61 | −$0.64 | −$1.00 | −$1.05 |
| Gross margin | — | — | — | — | — | — | −15.6% | — | — | — | −12.4% | — |
| Operating margin | — | — | — | — | — | — | −1,277.1% | — | — | — | −470.1% | — |
| Net margin | — | — | — | — | — | — | −1,363.5% | — | — | — | −429.4% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SLDB's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SLDB financial results
Solid Biosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $174.3 million. Diluted earnings per share came to −$2.02.
See the SLDB stock overview for the latest quote and news, or the SLDB chart for price history and technical indicators.
SLDB income statement FAQ
Does Solid Biosciences have revenue?
Solid Biosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Solid Biosciences profitable?
No. Solid Biosciences reported a net loss of $174.3 million in fiscal 2025.
How much does Solid Biosciences spend on research and development?
Solid Biosciences spent $140.3 million on research and development in fiscal 2025.
What are Solid Biosciences's earnings per share?
Solid Biosciences earned $-2.02 per diluted share in fiscal 2025, compared with $-3.04 a year earlier.
When will Solid Biosciences report its next earnings?
Solid Biosciences is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes.
When does Solid Biosciences's fiscal year end?
Solid Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.